Sapna Oberoi
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (25)
Year:
2026
Purpose Infants with cancer are rare and face unique challenges. Our study aims to describe the incidence of infantile cancers in Canada and to compare treatment‐related mortality (TRM) and their outcomes with those of older children. Methods We conducted a retrospective cohort study using the Cancer in Young People in Canada database, including all infants (0 to <1 year old) with newly diagnosed cancer from 2001 to 2020. Population‐based data were used to estimate annual cancer incidence. Cox proportional hazards models were used to compare TRM, event‐free survival (EFS) and overall survival (OS) between (1) neonates (<30 days old) and older infants (≥30 days to <1 year old, (2) younger (<6 months) and older infants (≥ 6 months), and (3) all infants with older children (≥1 to ≤10 years old). Results A total of 2256 infants were included. The incidence was 30.8 per 100,000 infant‐years, and this incidence increased with an annual percent change of 1.6%, p < 0.001. Neonates had significantly higher TRM (6.1 vs. 3.6%, HR 2.76, p < 0.001) as well as infants younger than 6 months (5.2 vs. 2.7%, HR 2.05, p < 0.001). Compared with older children, infants experienced higher risk of TRM (4.1 vs. 2.1%, HR 2.45, p < 0.001) and had inferior 5‐year EFS (66.2 vs. 68.6%, HR 1.27, p < 0.001) and OS (77.5 vs. 78.6%, HR 1.22, p < 0.001). Conclusion The annual incidence of infantile cancers in Canada has increased and their outcomes are significantly worse than those of older children, as they face a higher risk of TRM, particularly in younger infants. Précis The incidence of cancer in infants has increased significantly in Canada between 2001 and 2020 and their outcomes are significantly lower than those of older children, being at greater risk of TRM.
Year:
2026
Year:
2026
Year:
2026
The Molecular Characterization Initiative (MCI), a key effort of the National Cancer Institute’s Childhood Cancer Data Initiative (CCDI), was launched in 2022 in collaboration with the Children’s Oncology Group (COG) to bring comprehensive genomic and molecular profiling to children, adolescents, and young adults diagnosed with cancer. The MCI provides paired tumor and germline molecular testing, with results returned to clinicians to inform care. Deidentified data are made available to the research community through the CCDI Data Ecosystem to facilitate the discovery of new treatment strategies. This commentary outlines the MCI’s development, key accomplishments to date, and its role in laying the foundation for standardized clinical diagnostics in pediatric oncology.
Year:
2026
Year:
2026
Year:
2026
Introduction CIC‐rearranged sarcomas (CRS) are rare tumors predominantly affecting young adults. Despite distinct biology, CRS are often treated like Ewing sarcomas with multi‐agent chemotherapy, surgery, and radiotherapy, although the benefits of each remain unclear. We report the impact of treatment on response and survival. Methods This retrospective multicenter study included patients diagnosed with CRS between 2002 and 2023. Demographic, treatment, and outcome data were collected. Event‐free (EFS) and overall survival (OS) were estimated using Kaplan–Meier analysis; risk factors were assessed via log‐rank tests and Cox regression. Treatment response was assessed using RECIST. Results Among 27 patients (median age 21.5 years; range 8–83), 14 (52%) had localized and 12 (44%) metastatic disease (1 unknown). In the localized group, 6 (43%) received chemotherapy (Response: 2 complete, CR; 1 partial, PR; 1 mixed, MR; 1 stable, SD; 1 progressive disease, PD); 5 (36%) died—3 (21%) had received chemotherapy. Among metastatic patients, 10 (83%) received chemotherapy (1 CR, 5 PR, 2 MR, 1 PD); 9 died (one without chemotherapy). Local control was achieved in 12/14 (86%) localized and 7/12 (56%) metastatic patients. Only surgical resection was associated with improved OS (HR 0.13; p < 0.01) and EFS (HR 0.26; p < 0.01), particularly with R0 resection (EFS HR 0.23; p = 0.02). At median follow‐up of 18 months, 2‐year EFS was 56% vs. 8% ( p = 0.02) and OS was 67% vs. 23% ( p = 0.02) for localized vs. metastatic disease. Conclusion Complete resection is critical in CRS. Chemotherapy benefit remains uncertain, underscoring the need for improved local control and novel, biology‐driven therapies.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (26)
Sheila N. Garland
Professor
Memorial University
Douglas Hawkins
Professor
University of Washington
Raya Saab
Stanford University
Alice Soragni
University of California
Ajay Gupta
Assistant Professor
Roswell Park Comprehensive Cancer Center
Javed Khan
National Institutes of Health
Omar F Khan
Clinical Assistant Professor, Medical Oncology
University of Calgary Cumming School of Medicine
Mohamed Abdelaal
Assistant Professor
University of Ottawa
Zoe Walters
Professor
University of Southampton
Rebecca Deyell
Clinical Associate Professor
The University of British Columbia
Mark Hatley
Associate Member
St. Jude Children's Research Hospital
Jessica L. Davis
Indiana University School of Medicine
Catherine E. Cottrell
Nationwide Children's Hospital
Janet Shipley
Group Leader, Sarcoma Molecular Pathology
Institute of Cancer Research
David Douglass
Associate Professor
University of Arkansas for Medical Sciences
Susan M. Hiniker
Stanford University
Sharon H.J. Hou
Assistant Professor
Simon Fraser University
Jack Brzezinski
Associate Professor
University of Washington
Sara Israels
Professor
University of Manitoba
Jack Shern
Head, Tumor Evolution and Genomics Section
National Institutes of Health
Joshua Rash
Professor
University of Saskatchewan
Marie-Claude Pelland-Marcotte
Assistant Professor under scholarship
Laval University
Gianni Bisogno
Docenti di ruolo di Ia fascia
University of Padova
Alyson Mahar
Queen's University
Kenneth Wong
-
Lindsay Jibb
Assistant Professor
University of Toronto
Make your next move.
Prepare your application
Review drafts before you send them.